{"success":true,"data":{"pressRelease":{"id":"92066","rtpr_id":"nACSnYfpza","ticker":"EMBC","exchange":"NASDAQ","all_tickers":["EMBC"],"title":"EMBC Class Action: Embecta Investors Alerted to the Filed Securities Fraud Class Action - Legal Deadline Approaching on August 17","author":"ACCESSWIRE","published_at":"2026-07-19T10:07:13.342Z","article_body":"A securities fraud class action lawsuit has been filed on behalf of Embecta\ninvestors after its stock plummeted over 57% because Embecta allegedly misled\ninvestors regarding the strength of its insulin pen needle product category.\n\nNEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n19, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/nvgs) announces that a class action lawsuit has been filed\nagainst Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Embecta, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nKey Details of the Embecta ($EMBC) Class Action:\n*\nLead Plaintiff Deadline: August 17, 2026\n*\nAlleged Misconduct: Securities fraud relating to Embecta's statements about\nthe strength of its insulin pen needle product category.\n*\nLargest Alleged Stock Drop: May 5, 2026 - 57.8% Stock Drop\n*\nCourt: U.S. District Court for the District of New Jersey\n*\nAction: Contact BFA Law (https://pr.report/nvgv) to discuss your rights\n\nInvestors have until August 17, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nEmbecta common stock. The class action is pending in the U.S. District Court\nfor the District of New Jersey. It is captioned Apitz-Grossman v. Embecta\nCorp., et al., No. 26-cv-07217.\n\nWhy is Embecta Being Sued for Securities Fraud?\n\nEmbecta is a medical device company that produces insulin pens for patients\nwith diabetes. According to the complaint, during the relevant period, Embecta\ntouted the strength of its insulin pen portfolio stating that \"prescriptions\nfor insulin pens have been showing a slight positive trend . . . just\nexemplifying the resilience of this product portfolio.\"\n\nAs alleged, in truth, Embecta faced significant competition and \"overall\nmarket softness for insulin pens and pen needles.\"\n\nWhy did Embecta's Stock Drop?\n\nOn May 5, 2026, Embecta announced disappointing Q2 2026 results that came in\nbelow guidance due to share loss within its pen needle product category, most\nof which was from a single customer. Embecta also reported an \"overall market\nvolume softness for insulin pens and pen needles in the retail channel,\"\nadmitting that \"we have now begun to see a decline [for insulin pens] maybe\nmore pronounced in the most recent quarter that we reported.\" As a result,\nEmbecta also reduced its quarterly dividend from $0.15 to $0.01 per share.\n\nThis news caused the price of Embecta common stock to decline $5.35 per share,\nor 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5,\n2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Embecta, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar, Fonti, & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/embc-class-action-embecta-investors-alerted-to-the-filed-securit-1192733)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSnYfpza","title":"EMBC Class Action: Embecta Investors Alerted to the Filed Securities Fraud Class Action - Legal Deadline Approaching on August 17","author":"ACCESSWIRE","ticker":"EMBC","created":"2026-07-19T10:07:13.342Z","tickers":["EMBC"],"exchange":"NASDAQ","article_body":"A securities fraud class action lawsuit has been filed on behalf of Embecta\ninvestors after its stock plummeted over 57% because Embecta allegedly misled\ninvestors regarding the strength of its insulin pen needle product category.\n\nNEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n19, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/nvgs) announces that a class action lawsuit has been filed\nagainst Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Embecta, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nKey Details of the Embecta ($EMBC) Class Action:\n*\nLead Plaintiff Deadline: August 17, 2026\n*\nAlleged Misconduct: Securities fraud relating to Embecta's statements about\nthe strength of its insulin pen needle product category.\n*\nLargest Alleged Stock Drop: May 5, 2026 - 57.8% Stock Drop\n*\nCourt: U.S. District Court for the District of New Jersey\n*\nAction: Contact BFA Law (https://pr.report/nvgv) to discuss your rights\n\nInvestors have until August 17, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nEmbecta common stock. The class action is pending in the U.S. District Court\nfor the District of New Jersey. It is captioned Apitz-Grossman v. Embecta\nCorp., et al., No. 26-cv-07217.\n\nWhy is Embecta Being Sued for Securities Fraud?\n\nEmbecta is a medical device company that produces insulin pens for patients\nwith diabetes. According to the complaint, during the relevant period, Embecta\ntouted the strength of its insulin pen portfolio stating that \"prescriptions\nfor insulin pens have been showing a slight positive trend . . . just\nexemplifying the resilience of this product portfolio.\"\n\nAs alleged, in truth, Embecta faced significant competition and \"overall\nmarket softness for insulin pens and pen needles.\"\n\nWhy did Embecta's Stock Drop?\n\nOn May 5, 2026, Embecta announced disappointing Q2 2026 results that came in\nbelow guidance due to share loss within its pen needle product category, most\nof which was from a single customer. Embecta also reported an \"overall market\nvolume softness for insulin pens and pen needles in the retail channel,\"\nadmitting that \"we have now begun to see a decline [for insulin pens] maybe\nmore pronounced in the most recent quarter that we reported.\" As a result,\nEmbecta also reduced its quarterly dividend from $0.15 to $0.01 per share.\n\nThis news caused the price of Embecta common stock to decline $5.35 per share,\nor 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5,\n2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Embecta, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/embecta-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar, Fonti, & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/embc-class-action-embecta-investors-alerted-to-the-filed-securit-1192733)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-07-19T10:07:13.41241944Z","server_sent_at_ms":1784455633412},"received_at":"2026-07-19T10:07:13.477Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/embc-class-action-embecta-investors-alerted-to-the-filed-securit-1192733"},"analysis":{"id":"81113","press_release_id":"92066","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice naming Embecta; no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"stock_decline_percent":"57.8%","lead_plaintiff_deadline":"August 17, 2026"}},"quotedText":"All representation is on a contingency fee basis; there is no cost to you.","namedEntities":{"people":[{"name":"Adam McCall","role":"Contact"}],"products":[],"companies":[{"name":"Embecta Corp.","ticker":"EMBC","relationship":"target"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$5.35","context":"per share stock decline"},{"amount":"$9.25","context":"prior share price"},{"amount":"$3.90","context":"new share price"},{"amount":"$0.15","context":"prior quarterly dividend"},{"amount":"$0.01","context":"reduced quarterly dividend"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"EMBC"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice naming Embecta; no new disclosure from the company itself.\n\nThe release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{"customDimensions":{"stock_decline_percent":"57.8%","lead_plaintiff_deadline":"August 17, 2026"}},"named_entities":{"people":[{"name":"Adam McCall","role":"Contact"}],"products":[],"companies":[{"name":"Embecta Corp.","ticker":"EMBC","relationship":"target"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$5.35","context":"per share stock decline"},{"amount":"$9.25","context":"prior share price"},{"amount":"$3.90","context":"new share price"},{"amount":"$0.15","context":"prior quarterly dividend"},{"amount":"$0.01","context":"reduced quarterly dividend"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-19T10:10:36.619Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":108305,"modelName":"glm-4.7"}}